FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
|
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). |
1. Name and Address of Reporting Person*
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
NPS PHARMACEUTICALS INC [ NPSP ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
||||||||||||||||||||||||
3. Date of Earliest Transaction
(Month/Day/Year) 02/21/2015 | ||||||||||||||||||||||||||
4. If Amendment, Date of Original Filed
(Month/Day/Year) |
6. Individual or Joint/Group Filing (Check Applicable Line)
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 02/21/2015 | U | 276,955 | D | $46 | 0 | D |
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Stock Options | $38.27 | 02/21/2015 | D | 106,643 | (11) | 02/12/2024 | Common Stock | 106,643 | (1) | 0 | D | ||||
Stock Options | $8.23 | 02/21/2015 | D | 196,018 | (12) | 02/13/2023 | Common Stock | 196,018 | (1) | 0 | D | ||||
Stock Options | $8.21 | 02/21/2015 | D | 104,438 | (13) | 02/07/2022 | Common Stock | 104,438 | (1) | 0 | D | ||||
Stock Options | $8.25 | 02/21/2015 | D | 133,125 | (14) | 02/17/2021 | Common Stock | 133,125 | (1) | 0 | D | ||||
Stock Options | $3.34 | 02/21/2015 | D | 154,284 | (15) | 02/19/2020 | Common Stock | 154,284 | (1) | 0 | D | ||||
Stock Options | $3.25 | 02/21/2015 | D | 67,636 | (16) | 02/12/2020 | Common Stock | 67,636 | (1) | 0 | D | ||||
Stock Options | $5.71 | 02/21/2015 | D | 82,826 | (17) | 01/20/2019 | Common Stock | 82,826 | (1) | 0 | D | ||||
Stock Options | $5.71 | 02/21/2015 | D | 109,602 | (18) | 01/20/2019 | Common Stock | 109,602 | (1) | 0 | D | ||||
Restricted Stock Units | (2) | 02/21/2015 | D | 80,912 | (3) | (3) | Common Stock | 80,912 | (4) | 0 | D | ||||
Restricted Stock Units | (2) | 02/21/2015 | D | 19,598 | (5) | (5) | Common Stock | 19,598 | (4) | 0 | D | ||||
Restricted Stock Units | (2) | 02/21/2015 | D | 24,302 | (6) | (6) | Common Stock | 24,302 | (4) | 0 | D | ||||
Performance Units | (7) | 02/21/2015 | D | 27,926 | (8) | (8) | Common Stock | 27,926 | (9) | 0 | D | ||||
Performance Units | (7) | 02/21/2015 | D | 115,432 | (10) | (10) | Common Stock | 115,432 | (9) | 0 | D |
Explanation of Responses: |
1. In connection with the merger of Knight Newco 2, Inc. with and into NPS Pharmaceuticals, Inc. (the "Issuer") on February 21, 2015, each outstanding stock option, whether vested or unvested, was cancelled in exchange for a single lump sum cash payment in an amount equal to the product of (1) the number of shares of the Issuer's common stock subject to such stock option and (2) the execess, if any, of $46.00 over the exercise price per share of such stock option. |
2. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. |
3. On February 12, 2015, the Restricted Stock Units were granted with (i) one third vesting on the first anniversary of date of grant, (ii) one third on the second anniversary of date of grant and (iii) one third on the third anniversary of date of grant. |
4. In connection with the merger of Knight Newco 2, Inc. with and into the Issuer on February 21, 2015, each outstanding Restricted Stock Unit was cancelled in exchange for a lump sum cash payment in an amount equal to the product of (1) $46.00 and (2) the number of shares of common stock subject to such Restricted Stock Unit. |
5. On February 12, 2014, the Restricted Stock Units were granted with (i) one third vesting on the first anniversary of date of grant, (ii) one third on the second anniverary of date of grant and (iii) one third on the third anniverary of date of grant. |
6. On February 13, 2013, the Restricted Stock Units were granted with (i) one third vesting on the first anniversary of date of grant, (ii) one third on the second anniverary of date of grant and (iii) one third on the third anniverary of date of grant. |
7. Each performance unit represents a contingent right to receive one share of the Issuer's common stock. |
8. On February 12, 2014, the Performance Units were granted subject to vesting based on the satisfaction of certain performance criteria by the Issuer and/or the reporting person during the performance periods. |
9. In connection with the merger of Knight Newco 2, Inc. with and into the Issuer on February 21, 2015, each outstanding Performance Unit was cancelled in exchange for a lump sum cash payment in an amount equal to the product of (1) $46.00 and (2) the number of shares of common stock subject to such Performance Unit, which number was determined as if the applicable performance objectives had been achieved at the target performance level. |
10. On February 13, 2013, the Performance Units were granted subject to vesting based on the Issuer's satisfaction of certain performance criteria during the performance periods. |
11. On February 12, 2014, the stock options were granted with one fourth vesting on the first anniversary of date of grant and 6.25% vesting every three months thereafter. |
12. On February 13, 2013, the stock options were granted with one fourth vesting on the first anniversary of date of grant and 6.25% vesting every three months thereafter. |
13. On February 7, 2012, the stock options were granted with one fourth vesting on the first anniversary of date of grant and 6.25% vesting every three months thereafter. |
14. On February 17, 2011, the stock options were granted with one fourth vesting on the first anniversary of date of grant and 6.25% vesting every three months thereafter. |
15. On February 19, 2010, the stock options were granted with one fourth vesting on the first anniversary of date of grant and 6.25% vesting every three months thereafter. |
16. On February 12, 2010, the stock options were granted with one fourth vesting on the first anniversary of date of grant and 6.25% vesting every three months thereafter. |
17. On January 20, 2009, the stock options were granted with one fourth vesting on the first anniversary of date of grant and 6.25% vesting every three months thereafter. |
18. On January 20, 2009, the stock options were granted with one half vesting on the second anniversary of date of grant and one half vesting on the third anniversary of date of grant, with the actual number of options vesting on such dates determined based on specified performance criteria. |
/s/ Francois Nader, by Jill Thompson as attorney-in-fact | 02/24/2015 | |
** Signature of Reporting Person | Date | |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |